BRAF and cancer: Notably, a few tumors not affected by mutations in any of the three genes (but possibly mutated in other genes of the pathway) showed the same activated MAPK pathway transcriptional profile as the mutated cases, as it has been found in other cancers [17]; conversely, some mutated samples had a wild-type-like expression profile, including 10 cases carrying mutations with a low VAF; MM-295 (BRAF D594N); and PCL-026, harboring both D594N and E586K BRAF mutations.